Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | PRKX | P51817 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292025 | 0.89 | ROCK2 (0.71) | ROCK2AAK1MAOBIMPDH2 | |
| SCHEMBL22158355 | 0.89 | ROCK2 (0.71) | ROCK2AAK1MAOBIMPDH2 | |
| SCHEMBL30292024 | 0.89 | ROCK2 (0.71) | ROCK2AAK1MAOBIMPDH2 | |
| SCHEMBL22158349 | 0.86 | ROCK2 (0.58) | ROCK2AAK1MAOBRPS6KB1IMPDH2 | |
| SCHEMBL30292035 | 0.86 | ROCK2 (0.58) | ROCK2AAK1MAOBRPS6KB1IMPDH2 | |
| SCHEMBL22158319 | 0.84 | MAOB (0.68) | ROCK2MAOBRPS6KB1IMPDH2 | |
| SCHEMBL30292044 | 0.84 | MAOB (0.68) | ROCK2AAK1MAOBRPS6KB1IMPDH2 | |
| SCHEMBL22165399 | 0.84 | MAOB (0.68) | ROCK2AAK1MAOBRPS6KB1IMPDH2 | |
| SCHEMBL30292017 | 0.84 | MAOB (0.68) | ROCK2AAK1MAOBRPS6KB1IMPDH2 | |
| SCHEMBL30292055 | 0.84 | MAOB (0.68) | ROCK2MAOBRPS6KB1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | NR2E3, GFRA2, ALDH1A2 | ROCK2 389/4885AAK1 3347/4885CIT 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.